260 related articles for article (PubMed ID: 38299167)
1. Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors.
Tomlinson B; Wu QY; Zhong YM; Li YH
J Lipid Atheroscler; 2024 Jan; 13(1):2-20. PubMed ID: 38299167
[TBL] [Abstract][Full Text] [Related]
2. ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.
Akoumianakis I; Zvintzou E; Kypreos K; Filippatos TD
Curr Atheroscler Rep; 2021 Mar; 23(5):20. PubMed ID: 33694000
[TBL] [Abstract][Full Text] [Related]
3. Updates in Drug Treatment of Severe Hypertriglyceridemia.
Gouni-Berthold I; Schwarz J; Berthold HK
Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of therapies for chylomicronemia.
Shamsudeen I; Hegele RA
Expert Rev Clin Pharmacol; 2022 Apr; 15(4):395-405. PubMed ID: 35762447
[TBL] [Abstract][Full Text] [Related]
5. The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname MH; Rocha VZ; Santos RD
Curr Atheroscler Rep; 2021 Jun; 23(8):40. PubMed ID: 34146170
[TBL] [Abstract][Full Text] [Related]
6. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Gaudet D; Karwatowska-Prokopczuk E; Baum SJ; Hurh E; Kingsbury J; Bartlett VJ; Figueroa AL; Piscitelli P; Singleton W; Witztum JL; Geary RS; Tsimikas S; O'Dea LSL;
Eur Heart J; 2020 Oct; 41(40):3936-3945. PubMed ID: 32860031
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia.
Mohamed F; Botha TC; Raal FJ
Curr Opin Lipidol; 2021 Aug; 32(4):213-218. PubMed ID: 33883446
[TBL] [Abstract][Full Text] [Related]
8. APOC3 siRNA and ASO therapy for dyslipidemia.
Chebli J; Larouche M; Gaudet D
Curr Opin Endocrinol Diabetes Obes; 2024 Apr; 31(2):70-77. PubMed ID: 38334488
[TBL] [Abstract][Full Text] [Related]
9. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.
Wierzbicki AS; Viljoen A
Expert Opin Biol Ther; 2016 Sep; 16(9):1125-34. PubMed ID: 27248482
[TBL] [Abstract][Full Text] [Related]
10. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
Esan O; Wierzbicki AS
Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin-like 3: An important protein in regulating lipoprotein levels.
Burks KH; Basu D; Goldberg IJ; Stitziel NO
Best Pract Res Clin Endocrinol Metab; 2023 May; 37(3):101688. PubMed ID: 35999139
[TBL] [Abstract][Full Text] [Related]
12. Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3).
Ginsberg HN; Goldberg IJ
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):388-398. PubMed ID: 36579649
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside.
Ling P; Zheng X; Luo S; Ge J; Xu S; Weng J
Diabetes Obes Metab; 2021 Sep; 23(9):2020-2034. PubMed ID: 34047441
[TBL] [Abstract][Full Text] [Related]
14. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
17. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
18. A new dawn for managing dyslipidemias: The era of rna-based therapies.
Macchi C; Sirtori CR; Corsini A; Santos RD; Watts GF; Ruscica M
Pharmacol Res; 2019 Dec; 150():104413. PubMed ID: 31449975
[TBL] [Abstract][Full Text] [Related]
19. Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia.
Sosnowska B; Adach W; Surma S; Rosenson RS; Banach M
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614969
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.
Larouche M; Khoury E; Brisson D; Gaudet D
Curr Atheroscler Rep; 2023 Dec; 25(12):1101-1111. PubMed ID: 38095804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
